Oct
2026
Fiera Milano, Italy
Visit us
stand 7A50, Integrated Pharma

Polpharma S.A.

Exhibitor at CPHI Milan 2026
About Us

Polpharma Group. European business partner for pharmaceutical companies worldwide. Diversified business oportunities - API, CDMO, OL, In-licensing - supported by professional services and competencies dedicated to the B2B partners to grow beyond the scale together. We are offering environment for collaboration, support from qualified experts and state-of-the-art facilities. We are actively looking for partners in all of our activity areas – from product development stage, through production and commercial cooperation, to other forms of partnership.

Polpharma API

  • Country/Region:
    Poland
  • On CPHI since:
    2015
  • Certificates:
    4
  • Employees:
    5000+
Company types
CMO/CDMO
Contract Service
Generics/Biosimilars Manufacturer
Manufacturer/Innovator
Pharmaceutical company
Contact info
Event information
CPHI Milan 2026
  • 6 Oct 2026 - 8 Oct 2026
  • Fiera Milano, Italy
  • Visit us at stand 7A50, Integrated Pharma

Products Featured at CPHI Milan 2026

  • Acenocoumarol

    Product Acenocoumarol

    Therapeutic Area: Cardiovascular system
    EU DMF 
    Indication: Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist
    • Long experience in  in-house commercial manufacturing • No risk of  nitrosoamine presence
  • Acetazolamide

    Product Acetazolamide

    Therapeutic Area: Cardiovascular system 
    EU DMF
    US DMF

    Korean DMF
    Japanese DMF
    CEP available 
    Available also in injectable form Indication: Acetazolamide decreases the pressure in the eye and is used for adjunctive treatment of glaucoma, a condition in which increa...
  • Aripiprazole

    Product Aripiprazole

    Therapeutic Area: Nervous SystemEU DMF availableUS DMF no. 23314 availableCEP available Indication: used to treat the symptoms of psychotic conditions such as schizophrenia and bipolar disorder (manic depression). It is also used together with other medications to treat major depressive disorder in adult...
  • Carbamazepine

    Product Carbamazepine

    Therapeutic Area: Nervous System EU DMF availableUS DMF no. 26266 availableCEP available Indication: Carbamazepine is an anticonvulsant and mood-stabilizing drug used primarily in the treatment of epilepsy and bipolar disorder, as well as trigeminal neuralgia.
  • Carvedilol

    Product Carvedilol

    Therapeutic Area: Cardiovascular systemEU DMF availableUS DMF no. 17060 availableCEP available Indication: Carvedilol is a carbazole derivative acts as anti-hypertensive agent. It is formulated as tablets for oral route of administration. Carvedilol is indicated for the management of essential hypertens...

Polpharma Group Resources (1)

  • Brochure API Product List 2026

    Thanks to over 75 years of experience in process development, scale-up and cGMP manufacturing, we support both emerging and established pharmaceutical customers in the development and commercialization of their small molecule API clinical candidates and CDMO service. At our FDA-approved plant located in Central Europe, we provide end-to-end solutions from API development to scale-up allowing smooth process transfer for commercial-scale manufacturing capabilities, with world-class regulatory support. Our strong R&D management team, experienced in the development of chemical processes and complex projects, provides a wide range of solutions to our customers, applying a variety of chemical reactions and conditions, including cryogenic, High Pressure, strong base reactions, and tailor-made particle size distribution modifications. At Polpharma quality comes first. Regular FDA audits prove our reliability and credibility towards business partners around the world.